Abstract: A bone pore or void filling composition is described. The composition includes a mixture of: a type I collagen and/or a type I collagen-glycosaminoglycan coprecipitate; a blend of polyethylene glycol polymers having different molecular weights; a bone growth stimulator; and bioactive glass. A kit for containing the bone pore or void filling composition, and methods for using the composition to fill a bone pore or void are also described.

Abstract: The disclosure provides cosmetic and therapeutic compositions of alpha-adrenergic agents. Compositions of the disclosure may be used for topical, transdermal or parenteral administration to the eye or eyelid. The compositions of the disclosure may be used cosmetically to improve the appearance of the eye or therapeutically to treat ptosis.

Abstract: A food composition for managing non-food allergies in companion animals is disclosed, along with a method of managing non-food allergies.

Abstract: The present invention relates to a protein particle with a poorly water-soluble drug encapsulated therein and a preparation method therefor. The preparation method comprises the following steps: i) dissolving a poorly water-soluble drug and a liquid solubilizer into a good solvent; ii) partially or fully removing said good solvent from the product of step i); iii) mixing the product of step ii) with a protein; and iv) dispersing the product of step iii) in a poor solvent. The preparation method is simple and is suitable for industrial production.

Abstract: The invention relates to a cosmetic composition which comprises: (i) one or more anionic surfactants, (ii) at least 3.5% by weight of one or more fatty acids, relative to the total weight of the composition, and (iii) one or more antidandruff agents, the anionic surfactant(s)/fatty acid(s) weight ratio being from 0.5 to 3.5. The invention also relates to the use of said composition for washing and conditioning the hair.

Abstract: A pharmaceutical or nutraceutical composition having at least one inositol and resveratrol for use in a) preventive and/or curative treatment in metabolic disorders related to polycystic ovary syndrome; b) treatment to reduce symptoms associated with polycystic ovary syndrome such as menstrual cycle alterations and infertility; and/or c) to decrease glucose, triglyceride and BMI levels in subjects with metabolic syndrome.

Abstract: The present invention provides scaffolds that include a polymer and a cyclic peptide ligand. The peptide ligand increases the attachment of endothelial cells and/or progenitor cells to the scaffold. The present invention also provides engineered tissues that include the provided scaffolds. The present invention also provides coatings that include a coating polymer and a cyclic peptide ligand. The present invention also provides methods of improving endothelialization and vascularization of endothelial cells and/or progenitor cells for tissue regeneration in a subject and of repairing bone defects in a subject, by implanting a provided scaffold.

Abstract: The present invention a device for dispensing a composition, comprising: i) a dispensing head (1) intended to be fitted on a container that contains said composition, comprising: a body (3) that is open at its two opposite axial ends, an engaging part (10) that is open at its two opposite axial ends, at least partially defining at least one dispensing orifice (12), the cross section of the dispensing orifice being between 0.02 mm2 and 0.5 mm2, ii) the anhydrous composition comprising, in particular in a physiologically acceptable medium: a) at least one oily phase comprising at least one volatile hydrocarbon-based oil, and b) at least one clay, and c) at least one deodorant active agent, and d) at least one propellant. The present invention also relates to a method for the cosmetic treatment of body odor and optionally of human perspiration, which consists in applying to the surface of a keratin material a composition as defined above by means of the dispensing device defined above.

Abstract: A conjugated cationic dendrimer comprising end groups conjugated to charge-shielding groups, wherein some charge-shielding groups are chemically linked to active pharmaceutical ingredients.

Abstract: This invention relates to xanthohumol-based compositions, yielded in a hot-melt extrusion process (HME) using one or more water-soluble nutritionally and/or cosmetically acceptable thermoplastic polymers, such as selected from hydroxypropylmethyl-cellulose (HPMC), a vinylpyrrolidone-vinyl acetate copolymer, and combinations thereof. The present invention also relates to topical and oral formulations comprising such extruded xanthohumol-based compositions, as well as the use of one or more water-soluble nutritionally and/or cosmetically acceptable thermoplastic polymers in a hot-melt extrusion process of xanthohumol.

Abstract: The present invention relates to a hydrophilic foam material, which is of particular use in wound treatment, and to a method for producing said hydrophilic foam material. The hydrophilic foam material has nucleating particles, wherein at least 85% of all foam cells in said foam material have an average cell size of 0.01 mm2 or less.

Abstract: Disclosed are a medical fiberous structure and a method for preparing the same, wherein the medical fiberous structure comprises calcium carboxymethyl cellulose and a chitosan compound, at least one of the calcium carboxymethyl cellulose and the chitosan compound having a fibrous shape.

Abstract: Provided is a novel additive for an orally disintegrating tablet which imparts a rapid disintegration property and a tablet hardness to the orally disintegrating tablet and a method for producing the same. An additive for an orally disintegrating tablet according to one embodiment of the present invention includes a D-mannitol, a low-substituted hydroxypropyl cellulose (excluding those having a mean particle size of 20 ?m or less and a substitution degree of the hydroxypropoxy groups of 11%, having a mean particle size of 45 ?m or less and a substitution degree of the hydroxypropoxy groups of 14% and having a mean particle size of 45 ?m or less and a substitution degree of the hydroxypropoxy groups of 11% together with a 90% cumulated particle size of 100 ?m or less), a crospovidone and a crystalline cellulose.

Abstract: Synthesis and characterization of starch based pH-responsive nanoparticles for controlled drug delivery are described. Polymethacrylic acid grafted starch (PMAA-g-St) nanoparticles with various molar ratio of starch to MAA were synthesized by a new one-pot method that enabled simultaneous grafting of PMAA and nanoparticle formation in an aqueous medium. NMR data showed that polysorbate 80 was polymerized into the graft polymer. Nanoparticles were relatively spherical with narrow size distribution and porous surface morphology and exhibited pH-dependent swelling in physiological pH range. The particle size and magnitude of volume phase transition were dependent on PMAA content and formulation parameters such as surfactant levels, cross-linker amount, and total monomer concentration. The results showed that the new pH-responsive nanoparticles possessed useful properties for controlled drug delivery.

Abstract: A cleaning composition including a preservative formulation having hydroxy acetophenone and a phospholipid complex is disclosed. The cleaning composition can be loaded on a cleaning wipe and used for personal care. The hydroxyacetophenone provides a preservative booster to the preservative system for the cleaning composition containing a phospholipid complex, such as cocamidopropyl PG-dimonium chloride phosphate, which has some limited independent preservation activity, depending on the level in the final formulation.

Abstract: A digestive tract medication administration system and a medication administration capsule are provided. In an assembled state, with the constraint of a limit structure formed by a rotation limit pin on an inner shell of the capsule and a rotation limit slot in an outer shell of the capsule, and an angle exists between the N-S directions of the first magnetic column and the second magnetic column, a torque is present between the two magnetic columns, which makes parts inside the capsule tightly coupled. When an external magnetic field is applied, at least one or both of the two magnetic columns rotate under the action of the external magnetic field. When the external magnetic field is applied, the administration ports are in opened state, and when the external magnetic field is removed, the administration ports are in closed state.

Abstract: A stable dry powder composition for inhalation includes acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) in a range of about 1 ?m to about 5 ?m. The dry powder composition may contain a pharmaceutically acceptable excipient, such as a stearate, in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the composition.

Abstract: The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.

Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.

Abstract: The present invention relates to antimicrobial sanitizing compositions for use as skin sanitizers, especially sanitizers for the hands and feet, and air sanitizers and deodorisers. The sanitizing compositions comprise a combination of three ammonium compounds (ie. an alkoxy silyl ammonium compound, a benzalknonium chloride or benzethonium chloride and a polymeric biguanide) in a non-ionic surfactant carrier. The non-ionic surfactant system comprises an alcohol ethoxylate and an alkylglucoside or alkylpolyglycoside. Methods of use of the compositions are also described.